Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
Yahoo Finance · Sep 1, 2026 · Vertex Pharmaceuticals Inc (VRTX)
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.
Not investment advice. Cached headline, not a full reprint.